Chris JacobsBuy
Kura Oncology, Inc. · Transaction Dec 12, 2022 · Filed Jan 20, 2023 · $1,001 to $15,000
XNAS · KURA
+1.90% · +$0.2000 · Vol 680.7K
Live · updated 15:14:34 ET
Kura Oncology, Inc.
PHARMACEUTICAL PREPARATIONS
$10.73
Follow $KURA
One email when a member of Congress discloses a trade in it, with the official filing receipt linked.
Free. No account. Unsubscribe in one click.
Follow $KURA by emailVeridion Score
BETAHIGH CONF · 6 of 6 factors measuredTue Oct 6 · last completed session · daily score · 21h old · KURA
MethodologyKURA
Kura Oncology, Inc.
Tue Oct 6 · last completed session · daily score · 21h old
Lower range
Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.
Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
36/ 100
Veridion Score
Lower range · HIGH confidence · 6 of 6 factors measured
Sovereign · $25/mo
See why this score moved.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: HIGH · 6 of 6 factors measured · Tue Oct 6 · last completed session · daily score · 21h old
Veridion Score History · 90D
Loading score history
AI Analysis
SovereignWhy is KURA moving today?
Sovereign unlock connects news, insider activity, analyst moves, and live price action.
About Kura Oncology, Inc.
PHARMACEUTICAL PREPARATIONSListed since
2015
Employees
260
Country
US
Kura Oncology Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for the treatment of cancer. The company develops small-molecule medicines designed to target cancer signaling pathways in oncology and hematology. Its pipeline includes menin inhibitor ziftomenib for the treatment of acute myeloid leukemia and other hematologic malignancies, as well as additional product candidates such as KO-7246 and darolifarnib being evaluated for solid tumors and other diseases.
Key statistics
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Open
$10.43
Day high
$10.99
Day low
$10.32
Previous close
$10.53
52W high
$13.59
-21.04% from high
52W low
$7.40
54% of range
Market cap
$936.8M
EPS
$-3.3621
Beta
0.88
Shares out
89M
Volume
680.7K
0.34× rel vol
Avg volume
2M
VWAP
$10.75
Price history computed in-house
1W
+0.19%
1M
-19.02%
3M
-11.18%
1Y
+13.79%
YTD
+3.27%
SMA 50 $11.19 · below
SMA 200 $9.81 · above
52W position 54%
KURA overview
Related filings and maps
Public disclosures
Congress activity in KURA
1 filers · 1 buys · 0 sells (0 labeled S (partial)) · Dec 12, 2022 to Dec 12, 2022 · House 1 / Senate 0
All available history · Latest 1 of 1 lines · Read 2026-10-07T19:15:41.117Z
Official filing ↗
Federal contracts
KURA contract awards, year to date.
Public federal awards linked to this ticker.
Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for KURA in this window.
Lobbying spend
KURA lobbying filings, year to date.
Registered lobbying filings matched to Kura Oncology, Inc..
Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for KURA in this window.
Analyst ratings
Sovereign unlock shows live analyst consensus for KURA.
Options
Options data is temporarily unavailable. Changing your plan will not restore the upstream feed.